NCT00781586 is a Phase 4 clinical trial of One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350) in Energy Expenditure, sponsored by Bayer.

Who is sponsoring NCT00781586?

NCT00781586 is sponsored by Bayer.

What drugs are being tested in NCT00781586?

Interventions in NCT00781586: One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350), Caffeine, Placebo.

What condition does NCT00781586 study?

NCT00781586 studies Energy Expenditure.

Is NCT00781586 still recruiting?

NCT00781586 is currently completed. Last updated 19 December 2018.

Last reviewed 2018-12-19 · How we verify

NCT00781586

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.

Completed Phase 4 Last updated 19 December 2018

What this trial tests

Phase 4 trial testing One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350) in Energy Expenditure in 22 participants. Completed in 21 April 2008.

Timeline

2 October 2007

Primary endpoint
21 April 2008

21 April 2008

Quick facts

Lead sponsor	Bayer
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	prevention
Enrollment	22
Start date	2 October 2007
Primary completion	21 April 2008
Estimated completion	21 April 2008
Sites	1 location across United States

Drugs / interventions tested

One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)
Caffeine (caffeine) — full drug profile →
Placebo

Conditions studied

Energy Expenditure — all drugs for Energy Expenditure →

Sponsor

Bayer — full company profile →

Who can join

Adults 25 to 45, female only, with Energy Expenditure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is considered research because efficacy (how well a drug works) information is needed in healthy, 25-45 year-old, female subjects with moderate caffeine intake. The investigational product is available in the United States without a prescription (over-the-counter) as a nutritional supplement. The purpose of this study is to assess whether One-A-Day Weightsmart Advanced is safe and can increase metabolism and perceived energy in female subjects compared with caffeine or placebo (inactive drug). Participation in this study will last approximately 4 weeks and require about 4 outpatient visits to St. Luk's-Roosevelt Hospital Center. About 21 subjects are expected to participate in this study.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Small molecules for fat combustion: targeting obesity.
Liu J, Wang Y, Lin L. · · 2019 · cited 91× · PMID 30976490 · DOI 10.1016/j.apsb.2018.09.007
Clinical Application Potential of Small Molecules that Induce Brown Adipose Tissue Thermogenesis by Improving Fat Metabolism.
Lu KY, Primus Dass KT, Tsai SF, Chuang HM, et al · · 2020 · cited 2× · PMID 32854518 · DOI 10.1177/0963689720927394

Verify or expand the search:

Other recruiting trials for Energy Expenditure

Currently open trials in the same condition.

NCT07444021 — Effect of Resistance Exercise on Energy Balance and Appetite Regulation in Males and Females · NA · recruiting
NCT06962605 — Effects of Intermittent Running on Metabolic Health · NA · recruiting
NCT06951386 — The Impact of Daily Intake of Short-chain Fatty Acids on Cardiometabolic Risk Factors in Individuals at Risk for Metabol · NA · recruiting
NCT06477705 — The Energy Cost of 1-Hour Football Training · NA · recruiting
NCT06432517 — Sources and Mechanisms of Energy Compensation · NA · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00781586 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 19 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00781586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing